247 related articles for article (PubMed ID: 26147657)
1. Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors.
Liu X; Ling ZQ
Histol Histopathol; 2015 Oct; 30(10):1155-60. PubMed ID: 26147657
[TBL] [Abstract][Full Text] [Related]
2. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.
Clark O; Yen K; Mellinghoff IK
Clin Cancer Res; 2016 Apr; 22(8):1837-42. PubMed ID: 26819452
[TBL] [Abstract][Full Text] [Related]
3. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
5. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
Yang H; Ye D; Guan KL; Xiong Y
Clin Cancer Res; 2012 Oct; 18(20):5562-71. PubMed ID: 23071358
[TBL] [Abstract][Full Text] [Related]
6. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
7. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
Ohba S; Hirose Y
Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
[TBL] [Abstract][Full Text] [Related]
8. Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
Waitkus MS; Diplas BH; Yan H
Cancer Cell; 2018 Aug; 34(2):186-195. PubMed ID: 29805076
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
[TBL] [Abstract][Full Text] [Related]
10. IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.
Krell D; Mulholland P; Frampton AE; Krell J; Stebbing J; Bardella C
Future Oncol; 2013 Dec; 9(12):1923-35. PubMed ID: 24295421
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
[TBL] [Abstract][Full Text] [Related]
13. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
15. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
Sharma H
Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Kato Kaneko M; Ogasawara S; Kato Y
Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
[TBL] [Abstract][Full Text] [Related]
17. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Ma R; Yun CH
Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
[TBL] [Abstract][Full Text] [Related]
19. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.
Borodovsky A; Seltzer MJ; Riggins GJ
Curr Opin Oncol; 2012 Jan; 24(1):83-9. PubMed ID: 22080945
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
Avellaneda Matteo D; Grunseth AJ; Gonzalez ER; Anselmo SL; Kennedy MA; Moman P; Scott DA; Hoang A; Sohl CD
J Biol Chem; 2017 May; 292(19):7971-7983. PubMed ID: 28330869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]